Alaunos Therapeutics, Inc. (TCRT) shareholders
Close on Nov 18, 2026Market cap $4.37MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Harwin Peter Evan Joint filing with Fairmount Funds Management LLC (19.99%), Fairmount Healthcare Co-Invest VII L.P. (19.99%) and 1 more | 858,789 | 19.99% | 13D (active) | Oct 13, 2026 |
| Postma Robert W Joint filing with WaterMill Asset Management Corp. (9.99%) | 514,691 | 9.99% | 13D (active) amendment | Oct 13, 2026 |
| Price Adrian | 189,061 | 8.60% | 13D (active) amendment | Feb 24, 2026 |
| PMGC Holdings Inc. Joint filing with Pmgc Capital LLC (5.09%) | 83,500 | 5.09% | 13D (active) | May 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TCRT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 21,353 | 0.84% | $48.26K | – | 0.00% |
| Geode Capital Management, LLC | 19,356 | 0.76% | $43.75K | −3,204 | 0.00% |
| Vanguard Fiduciary Trust Co | 15,497 | 0.61% | $35.02K | – | 0.00% |
| Vanguard Capital Management LLC | 14,063 | 0.55% | $31.78K | – | 0.00% |
| Citadel Advisors LLC | 11,870 | 0.47% | $26.83K | +1,351 | 0.00% |
| Osaic Holdings, Inc. | 1,731 | 0.07% | $3.91K | −48 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,621 | 0.06% | $3.66K | +38 | 0.00% |
| SRS Capital Advisors, Inc. | 1,216 | 0.05% | $2.75K | New | 0.00% |
| UBS Group AG | 992 | 0.04% | $2.24K | −1,282 | 0.00% |
| Morgan Stanley | 836 | 0.03% | $1.89K | +183 | 0.00% |
| Vanguard Global Advisers, LLC | 501 | 0.02% | $1.13K | – | 0.00% |
| Wells Fargo & Company/Mn | 388 | 0.02% | $877 | +198 | 0.00% |
| Royal Bank of Canada | 375 | 0.01% | $1.00K | +190 | 0.00% |
| Ronald Blue Trust, Inc. | 135 | 0.01% | $305 | – | 0.00% |
| Steward Partners Investment Advisory, LLC | 112 | 0.00% | $253 | +20 | 0.00% |
| Federation des caisses Desjardins du Quebec | 70 | 0.00% | $158 | – | 0.00% |
| Bokf, NA | 66 | 0.00% | $149 | New | 0.00% |
| Axiom Investment Management LLC | 46 | 0.00% | $104 | New | 0.00% |
| Key Financial Inc | 24 | 0.00% | $54 | – | 0.00% |
| Signaturefd, LLC | 23 | 0.00% | $52 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 29 | 0M | 3.6% | 6 / 6 | 3 / 4 | 0M | 0M |
| Q1 2026 | 29 | 0M | 5.0% | 6 / 6 | 4 / 2 | 0M | 0M |
| Q4 2025 | 27 | 0M | 4.3% | 6 / 2 | 6 / 5 | 0M | 0M |
| Q3 2025 | 26 | 0M | 2.6% | 4 / 3 | 6 / 6 | 0M | 0M |
| Q2 2025 | 28 | 0M | 2.8% | 3 / 3 | 7 / 4 | 0M | 0M |
| Q1 2025 | 29 | 0M | 2.8% | 4 / 3 | 6 / 4 | 0M | 0M |
| Q4 2024 | 30 | 0M | 2.8% | 6 / 2 | 12 / 5 | 0M | 0M |
| Q3 2024 | 29 | 0M | 7.6% | 28 / 0 | 1 / 2 | 0M | 0M |
| Q2 2024 | 3 | 0M | 0.0% | 3 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held TCRT in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TCRT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 15,224 | 0.60% | $44.45K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 14,063 | 0.55% | $31.78K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 2,376 | 0.09% | $6.94K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 2,317 | 0.09% | $6.77K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,117 | 0.04% | $3.26K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dale Curtis Hogue Jr. | See Remarks, Director | – | – | Apr 1, 2025 |
| Holger Weis | CEO | 68,247 | 2.69% | Oct 8, 2026 |
| Ferdinand Groenewald | Vice President of Finance | 10,775 | 0.42% | Aug 20, 2025 |
| Melinda Lackey | Legal & Administration | – | – | Apr 1, 2025 |
| Healthcare Co-Invest VII L.P. Fairmount | Director, 10% owner | – | – | Oct 15, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | – | – | Oct 15, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | 687,789 | 27.07% | Oct 15, 2026 |
| Peter Evan Harwin | Director, 10% owner | – | – | Oct 15, 2026 |
| Robert W. Postma | Director | 142,878 | 5.62% | Oct 8, 2026 |
| Jaime Vieser | Director | 85,914 | 3.38% | Oct 8, 2026 |
| Michael Allen Jerman | Director | 44,749 | 1.76% | Oct 8, 2026 |
| Tomas Kiselak | 10% owner | – | – | Oct 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Allen Jerman Director | Oct 6, 2026 | Award | +20,990 | $0.74 | $15.62K | 44,749 |
| Jaime Vieser Director | Oct 6, 2026 | Award | +22,669 | $0.74 | $16.87K | 70,311 |
| Holger Weis CEO | Oct 6, 2026 | Award | +23,564 | $0.74 | $17.54K | 49,047 |
| Robert W. Postma Director | Oct 6, 2026 | Award | +21,829 | $0.74 | $16.25K | 80,438 |
| Holger Weis CEO | Aug 6, 2026 | Award | +4,363 | $2.01 | $8.77K | 25,483 |
| Robert W. Postma Director | Jul 23, 2026 | Award | +8,463 | $1.92 | $16.25K | 58,609 |
| Holger Weis CEO | Jul 23, 2026 | Award | +4,568 | $1.92 | $8.77K | 21,120 |
| Jaime Vieser Director | Jul 23, 2026 | Award | +8,789 | $1.92 | $16.87K | 47,642 |
| Michael Allen Jerman Director | Jul 23, 2026 | Award | +8,138 | $1.92 | $15.62K | 23,759 |
| Holger Weis Chief Executive Officer | Jun 30, 2026 | Award | +3,880 | $2.26 | $8.77K | 16,552 |
| Holger Weis Chief Executive Officer | Jun 12, 2026 | Award | +7,761 | $2.26 | $17.54K | 12,672 |
| Holger Weis Chief Executive Officer | May 22, 2026 | Award | +3,700 | $2.37 | $8.77K | 4,911 |
| Jaime Vieser Director | Apr 29, 2026 | Award | +6,515 | $2.59 | $16.87K | 38,853 |
| Michael Allen Jerman Director | Apr 29, 2026 | Award | +6,032 | $2.59 | $15.62K | 15,621 |
| Robert W. Postma Director | Apr 29, 2026 | Award | +6,274 | $2.59 | $16.25K | 50,146 |
| Michael Allen Jerman Director | Jan 12, 2026 | Award | +5,406 | $2.89 | $15.62K | 9,589 |
| Robert W. Postma Director | Jan 12, 2026 | Award | +5,622 | $2.89 | $16.25K | 43,872 |
| Jaime Vieser Director | Jan 12, 2026 | Award | +5,839 | $2.89 | $16.87K | 32,338 |
| Jaime Vieser Director | Nov 21, 2025 | Award | +5,340 | $3.16 | $16.87K | 26,499 |
| Michael Allen Jerman Director | Nov 21, 2025 | Award | +4,183 | $3.16 | $13.22K | 4,183 |
| Robert W. Postma Director | Nov 21, 2025 | Award | +5,142 | $3.16 | $16.25K | 38,250 |
| Ferdinand Groenewald Vice President of Finance | Aug 18, 2025 | Award | +10,775 | – | – | 10,775 |
| Robert W. Postma Director | Jul 3, 2025 | Award | +4,050 | – | – | 33,133 |
| Jaime Vieser Director | Jul 3, 2025 | Award | +3,400 | – | – | 21,159 |
| Robert W. Postma Director | Apr 13, 2025 | Award | +20,804 | $2.92 | $60.75K | 29,083 |
| Jaime Vieser Director | Apr 13, 2025 | Award | +17,465 | – | – | 43,359 |
| Robert W. Postma Director | Apr 13, 2025 | Award | +20,804 | $2.92 | $60.75K | 29,083 |
| Jaime Vieser Director | Dec 31, 2024 | Sale | −818 | $2.00 | $1.64K | 25,894 |
| Jaime Vieser Director | Dec 31, 2024 | Sale | −2,182 | $2.01 | $4.39K | 26,712 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Sep 1, 2023 | Sale(10b5-1 plan) | −68,014 | $0.14 | $9.52K | 798,236 |
| Jaime Vieser Director | Nov 29, 2022 | Buy | +1,250,000 | $0.65 | $812.50K | 1,250,000 |
| Robert W. Postma Director | Nov 29, 2022 | Buy | +750,000 | $0.65 | $487.50K | 5,000,000 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Aug 30, 2022 | Tax withholding | −18,750 | $2.41 | $45.19K | 866,250 |
| Christopher Bowden Director | Jun 22, 2022 | Award | +40,000 | – | – | 44,167 |
| James Huang Director | Jun 22, 2022 | Award | +80,000 | – | – | 188,333 |
| James Huang Director | Jun 22, 2022 | Award | +80,000 | – | – | 188,333 |
| Holger Weis Director | Jun 22, 2022 | Award | +40,000 | – | – | 160,167 |
| Robert W. Postma Director | Jun 22, 2022 | Award | +40,000 | – | – | 1,241,870 |
| Mary Thistle Director | Jun 22, 2022 | Award | +40,000 | – | – | 45,000 |
| Jaime Vieser Director | Jun 22, 2022 | Award | +40,000 | – | – | 745,321 |
| Robert W. Postma Director | Jun 22, 2022 | Award | +40,000 | – | – | 1,241,870 |
| Mary Thistle Director | Jun 22, 2022 | Award | +40,000 | – | – | 45,000 |
| Groot Eleanor De EVP, Operations | Dec 22, 2021 | Sale(10b5-1 plan) | −20,132 | $1.27 | $25.57K | 237,106 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Nov 17, 2021 | Buy | +9,116 | $1.40 | $12.76K | 885,000 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Nov 16, 2021 | Buy | +884 | $1.40 | $1.24K | 875,884 |
| Jaime Vieser Director | Sep 29, 2021 | Buy | +100,000 | $1.91 | $191.00K | 705,321 |
| Robert W. Postma Director | Sep 2, 2021 | Buy | +54,492 | $1.73 | $94.27K | 4,250,000 |
| Robert W. Postma Director | Sep 2, 2021 | Buy | +20,508 | $1.73 | $35.48K | 1,201,870 |
| Heidi Hagen Director | Sep 2, 2021 | Buy | +23,770 | $1.76 | $41.84K | 145,889 |
| James Huang Director | Sep 1, 2021 | Buy | +100,000 | $1.71 | $171.00K | 108,333 |
| Holger Weis Director | Sep 1, 2021 | Buy | +50,000 | $1.83 | $91.50K | 120,167 |
| Kevin S. Boyle Sr. Chief Executive Officer, Director | Aug 30, 2021 | Award | +875,000 | – | – | 875,000 |
| Raffaele Baffa Chief Medical Officer | May 17, 2021 | Award | +80,645 | – | – | 280,645 |
| J. Kevin Buchi Director | Mar 4, 2021 | Award | +4,167 | – | – | 4,167 |
| Jaime Vieser Director | Mar 4, 2021 | Award | +4,167 | – | – | 605,321 |
| James Huang Director | Mar 4, 2021 | Award | +8,333 | – | – | 8,333 |
| Holger Weis Director | Mar 4, 2021 | Award | +4,167 | – | – | 70,167 |
| Robert W. Postma Director | Mar 4, 2021 | Award | +2,500 | – | – | 1,181,362 |
| Mary Thistle Director | Mar 4, 2021 | Award | +5,000 | – | – | 5,000 |
| Christopher Bowden Director | Mar 4, 2021 | Award | +4,167 | – | – | 4,167 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alaunos Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 840,991 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jaime Vieser Director | Dec 31, 2024 | 3,000 | $6.51K | Dec 31, 2024 | Open Market Purchase |
| Boyle Kevin S. Sr. Officer | Sep 1, 2023 | 70,401 | $9.50K | Sep 1, 2023 | VESTING OF RESTRICTED STOCK |
See a number that looks wrong?